Tekmira Pharmaceuticals

Tekmira Pharmaceuticals is biopharmaceutical company focused on discovering, developing and commercializing a cure - especially cure for patients who suffer from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They are developing a pipeline focused on Non-HBV Assets  that influence their RNA interference (RNAi) therapeutics and expertise in Lipid Nanoparticle (LNP) technology. RNAi and LNP technology has the ability to produce new drugs that take advantage of the body’s own natural processes to silence disease causing genes or reduce specific gene-products from the cell. Their LNP technology introduces the most widely adopted delivery technology in RNAi.